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Abstract 
Objective: To explore the association between depressive symptom history and cancer 
incidence. 
Methods: Affective/emotional depressive symptoms were assessed using the General 
Health Questionnaire (GHQ-30) depression sub-scale across phase 1 (1985-1988), phase 2 
(1989-1990), and phase 3 (1991-1994) of the Whitehall II prospective cohort study; 
‘chronic’= depressive episode at phase 1, 2 and 3; ‘new’= depressive episode at phase 3 
only. Cancer Incidence was obtained from the National Health Service Central Register with 
an average follow-up of 15.6 years (range 0.08–17.4). The study sample consisted of 6983 
participants, aged 35–55 years at baseline. Results were adjusted for age, sex, socio-
economic position, health behaviours, health status/conditions, medication, and social 
support. 
Results: Over a 17.4 year follow-up, chronic depressive symptoms did not increase the risk 
of cancer incidence compared to those who never experienced symptoms (hazard ratio 
(HR)=1.03, 95% confidence interval (CI): 0.71-1.49).  Participants who experienced new 
depressive symptoms had an increased risk of cancer incidence in the first 9 years of follow-
up (HR=1.89, 95% CI: 1.23-2.90) but no increased risk in later years (HR=0.84, 95% CI: 
0.52-1.35).  
Conclusion: Chronic depressive symptoms were not associated with cancer incidence. In 
contrast, new-onset symptoms were associated with a substantially increased risk, possibly 
due to reverse causality. 
 
Key words: cancer; depressive symptoms; depression; longitudinal studies; psycho-
oncology.  
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Introduction 
Meta-analyses indicate that depressive symptoms are a risk factor for both cancer incidence 
and mortality [1–3], although there is large disparity among associations from individual 
studies. Mixed findings can be attributed to methodological factors, such as failure to 
adequately control for potential confounders [4–6], differences in study sample 
characteristics [3], and inadequate measures of depression [4]. There are also potential 
difficulties surrounding the accuracy of depression diagnosis among those with physical 
illnesses due to somatic symptom overlap. For example, symptoms such as fatigue, loss of 
appetite, and general malaise, could be due to depression, or ‘sickness behaviour’ as a 
result of cancer or comorbid illness. [7–9]. In addition, no study has taken into account a 
participants' history of depression, which could be an important determinant of cancer 
incidence. For example, new-onset/recent depressive symptoms have been shown to 
increase the risk of cardiovascular events [10,11] and all-cause mortality [12]. 
 
There are several possible biological and behavioural pathways by which the association 
between depression and cancer incidence may be explained. Firstly, depression may have a 
direct effect on the immune system through dysregulation of the hypothalamic-pituitary-
adrenal (HPA) axis [4,13–15]. Secondly, depression may indirectly lead to cancer through 
behavioural pathways, such as smoking, alcohol consumption, and low levels of physical 
activity [16–19]. Equally, depressed patients may be less likely to attend routine health 
checks, and have poorer adherence to treatment regimens [20,21]. A third consideration is 
the possibility of reverse causality whereby sub-clinical cancer may cause depression as a 
result of an inflammatory response [22–25].  
 
This is the first study known to the authors to use repeated measures of depression to 
explore the association between depressive symptom history and cancer incidence. It is also 
the first to isolate the role of affective/emotional depressive symptoms, which are less likely 
to be confounded by somatic symptoms of poor physical health, such as fatigue or tiredness. 
A further strength includes data on a wide range of potential confounders and mediators. 
 
Methods 
 
Participants 
The target population for the Whitehall II study was all London-based office staff aged 33-55 
working in 20 civil service departments, covering a wide range of employment grades from 
low to high incomes. With a response rate of 73%, the study recruited 10,308 participants; 
6895 men and 3413 women at phase 1 (1985-1988) [26]. Phase 2 (1989-1990) comprised of 
8132 participants (79% of phase 1 responders), and phase 3 (1991-1994) comprised of 
8815 participants (86% of phase 1 responders). Mean follow-up for cancer incidence after 
phase 3 was 15.6 years (range 0.08 to 17.4), with a total 109,209 person-years and 776 
incident cancers.  
 
Depressive Symptoms 
At phases 1, 2 and 3, participants completed the 30-item General Health Questionnaire 
(GHQ-30) [27,28] which is used to detect minor psychiatric disorders in non-psychiatric 
populations [29,30]. A four-item depressive symptom sub-scale was derived (Cronbach’s α: 
0.88) based-on principal components factor analysis [31,32]. The scale has been compared 
with the validated seven-item depression subscale of the 28-item GHQ [33], and the test-
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retest reliability was r=0.78 in a sample of 286 participants who repeated the GHQ 
depression sub-scale within 1 month [33]. Participants were asked whether, over the last few 
weeks, they had: ‘been thinking of yourself as a worthless person’; ‘felt that life is entirely 
hopeless’; ‘felt that life isn’t worth living’; and, ‘found at times you couldn’t do anything as 
your nerves were so bad’.  These 4-items assess the affective/emotional symptoms of 
depression only, and do not cover somatic symptoms, such as tiredness, pain, or sleep 
disturbance. Items were scored on a four-point scale (0= ‘not at all’, 1= ‘no more than usual’, 
2= ‘rather more than usual’, 3= ‘much more than usual’), giving a range from 0 – 12. 
Participants were defined as experiencing an ‘episode of depressive symptoms’, if they had 
a sum score of 4 or more. This cut point, as used in previous studies, results in a prevalence 
rate similar to that of clinical depression in the general UK population [33–35]. The 
dichotomised GHQ depression sub-scale was used to create the following two exposure 
variables: Depression Incidence and Depression History. 
 
‘Depression Incidence’ indicates the number of times a participant experienced an episode 
of depressive symptoms across phases 1 to 3. Participants who did not experience an 
episode of depressive symptoms at phase 1, 2 or 3, were classed as having ‘never’ 
experienced depressive symptoms. Those who reported an episode at all three phases were 
classed as experiencing ‘chronic’ depressive symptoms, as defined previously by Penninx et 
al. [10]. 
 
‘Depression History’ refers to the temporal arrangement of depressive symptom episodes. 
Over three-quarters of depressive and anxiety disorders begin prior to age twenty-four, 
whilst new-onset disorder in adulthood remains relatively rare [36–38]. To ensure the highest 
probability of capturing emerging depressive symptoms, participants who had a depressive 
episode at phase 3, but not at phase 1 or 2 were classified as experiencing ‘new’ depressive 
symptoms, as previously defined by Penninx et al. [10]. ‘Never’ and ‘chronic’ depressive 
symptoms were defined in the same way as the Depression Incidence variable. All other 
participants who experienced a depressive symptom episode once or twice across phases 1 
to 3 were classified as experiencing a history of ‘non-chronic’ depressive symptoms. 
 
Cancer incidence 
Cancer incidence data for 1971-2008 were obtained from the National Health Service 
Central Register (NHSCR) for nearly all participants (n=10,297). Cancer sites in cancer 
registry data were coded according to International Classification of Diseases revision 9 
(ICD-9) in 1971-1994, and revision 10 (ICD-10) from 1995 onwards. Incidence of malignant 
cancer was defined as ICD-9 codes 140-208 or ICD-10 codes COO-C97. Follow-up time 
was from phase 3 to first incident cancer, or censored at death or end 2008. Total incident 
cancer was 776, this included 109 smoking-related, 311 hormone-related, and 356 other. 
Hormone related cancers were breast (ICD9 174; ICD10 C50), cervix (180; C53), corpus 
uteri (182; C54), ovary (183; C56), and prostate (185; C61). Smoking-related cancers were 
considered to be oral cavity (ICD9 140-149; ICD10 C00-C06, C09-C14), oesophagus (150; 
C15), pancreas (157; C25), respiratory and intrathoracic organs (160-163; C30-C34, C38), 
and urinary tract (188-189; C64-C68)  [39]. 
 
Covariates 
4 
 
Variables believed to be associated with both depression and cancer incidence were 
included as covariates in the analysis, and were obtained at phase 3 unless otherwise 
indicated.  
Demographic data included age and sex. Socio-economic position was indexed by 
civil service employment grade, ranging from 1 (highest) to 6 (lowest) [26].  
Measures of health status obtained from clinical screening included body-mass-index 
(BMI in kg/m2, grouped into quintiles) and systolic blood pressure (mmHg, grouped into 
quintiles). Self-reported ‘health in the last year’ was assessed using a 5 point scale (very 
good, good, average, poor, very poor).  
Health conditions included self-reported respiratory illness (yes/no), and presence of 
longstanding illness (yes/no).  
Medication use included self-reported ‘antidepressant use in the last 14 days’ at 
phase 1 (yes/no).  
 
Health behaviours were categorised as follows: smoking (non-smoker, ex-smoker, 1-10 per 
day, 11-20 per day, and 21+ per day); alcohol consumption (units per week, grouped into 
quintiles); fruit and vegetable consumption (0-2 per week, 3-4 per week, 5-6 per week, daily, 
and 2+ per day); meat consumption (0-3 per month, 1-2 per week, 3-4 per week, 5-6 per 
week, and daily); and physical activity (number of hours of mild/moderate/vigorous physical 
activity per week). 
 
Social support measures were obtained from phase 2, and included ‘emotional support’ 
(seven-item scale measuring confiding, boosting self-esteem, sharing interests and 
reciprocity), ‘practical support’ (four-item scale measuring the level of practical help 
received), and ‘negative aspects of social support’ (four-item scale measuring the 
inadequacy of the closest person to deliver support [31]. These measures were based on the 
person nominated as closest in the Close Persons Questionnaire [40], which has been 
validated against the Self Evaluation and Social Support Interview in a sample of 201 Civil 
Servants [40]. Social support measures were grouped into tertiles representing low, medium 
and high support. 
 
Missing data 
There were missing data for the following covariates: employment grade (n=6, 0.1%); 
smoking (n=232, 3.3%); alcohol consumption (n=6, 0.1%); meat consumption (n=10, 0.1%); 
body mass index (n=310, 4.4%); systolic blood pressure (n=306, 4.4%), fruit and vegetable 
consumption (n=7, 0.1%);respiratory illness (n=5, 0.1%), health in the last year (n=8, 0.1%); 
antidepressant use (question introduced only partway through phase 1 data collection, 
n=1748, 25.0%); practical support (n=258, 3.7%); emotional support (n=277, 4.0%); and 
negative aspects of social support (n=278, 4.0%). Overall 12.8% of records had missing 
covariate data (34.7% if including antidepressant use); therefore, multiple imputation (mi 
command in Stata 12.0) [41,42] was used to impute missing data for covariates. Analysis 
models were run with ten imputations.  
 
Statistical Analysis 
All analyses were conducted using Stata 12.0. To assess the characteristics of the study 
sample, continuous variables were grouped to allow the calculation of rate-ratios using the 
Mantel-Haenszel method. Kaplan-Meier graphs were produced to show the unadjusted 
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relationship between Depression Incidence/Depression History and cancer incidence over 
time. Log-rank tests were used to test the equality of survival curves. 
 
The relationship between Depression Incidence/Depression History and cancer incidence 
was explored using Cox Regression models [43]. All models were first adjusted for age and 
sex. Second, covariates were grouped into measures of socio-economic position, health 
behaviours, health status, health conditions, social support and medication (defined 
previously) and the impact of each group was assessed in turn. Third, all covariates were 
then added into the model and likelihood ratio χ2 tests (LRT) were used to assess whether 
covariates were independent predictors of cancer incidence. Finally, if a covariate did not 
predict cancer incidence, and its removal from the model did not affect the Depression 
Incidence/Depression History hazard-ratios, then it was excluded from the final model.  
 
The proportional hazards assumption was assessed using the Schoenfeld Residuals 
method. Where there was evidence against the proportional hazards assumption, piecewise 
Cox regression was used to estimate separate hazard ratios for early and later follow up. 
Interactions coefficients were examined between Depression Incidence/Depression History 
and each of the covariates. If necessary, covariates were reclassified into fewer categories 
to ensure cancer incidence was not zero among interaction sub-categories. 
 
Sensitivity analyses involved the inclusion of a 3-year wash-out period to test whether 
depressive symptoms occurred as a result of suspected cancer prior to diagnosis. The 
association between Depression Incidence/History and cancer incidence was also examined 
by cancer type. 
 
Results 
Excluded participants 
Of the 10,308 participants in the Whitehall II study, 3325 were excluded from analysis 
leaving a study sample of 6983. Reasons for exclusion were non-response (n=2176) or 
death (n=125) before phase 3, no link to cancer registry (n=11), previous cancer incidence 
(cancer registry n=139; self-reported n=12), and missing GHQ data at either phase 1, 2 or 3 
(n=987). Participants were not included if they had GHQ data at two phases only as it was 
considered questionable to make assumptions about the chronicity or history of depressive 
symptoms based on only two time points. 
 
Cox regression analysis showed there was no difference in cancer incidence risk between 
excluded participants and study sample participants after adjustment for age and sex 
(hazard ratio (HR)=1.08, 95% confidence interval (CI): 0.95, 1.23); however 
inclusion/exclusion was associated with employment grade, smoking, self-reported health, 
fruit and vegetable consumption and physical activity (χ2 all P < 0.002). Excluded 
participants were more likely to smoke, be clerical and support staff, eat fewer fruit and 
vegetables, do fewer hours of physical activity, and report poorer health in the last year. 
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Table 1. Descriptive characteristics of the study sample and crude cancer incidence rates 
(n=6983, 776 incident cancer). 
Characteristic N % Inciden
t 
cancer 
Rate (per 
1000 
pyrs) 
Rate ratio  
(95% CI) Depression 0 - Never 5167 74.0 589 7.29 1 (ref) 
Incidencea 1 occasion 1084 15.5 114 6.75 0.93 (0.76 to 1.13) 
 
2 occasions 470 6.7 42 5.68 0.78 (0.57 to 1.07) 
 
3 - Chronic 262 3.8 31 7.61 1.04 (0.73 to 1.50) 
       
Depression  Never 5,167 74.0 589 7.29 1 (ref) 
Historyb New  346 5.0 42 7.94 1.09 (0.80 to 1.49) 
 
Non-
chronic 
1,208 17.3 114 6.00 0.82 (0.67 to 1.00) 
 
Chronic 262 3.8 31 7.61 1.04 (0.73 to 1.50) 
       
Age group 35-39 1932 27.7 106 3.40 1.0 
 
40-44 1794 25.7 166 5.79 1.70 (1.33 to 2.17) 
 
45-49 1419 20.3 160 7.25 2.13 (1.67 to 2.73) 
 
50-56 1838 26.3 344 12.62 3.71 (2.99 to 4.62) 
       
Sex Male 4856 69.5 507 6.66 1.0 
 
Female 2127 30.5 269 8.14 1.22 (1.06 to 1.42) 
       
Employment  1 - High 1217 17.4 163 8.57 1 (ref) 
grade 2 1510 21.6 158 6.66 0.78 (0.63 to 0.97) 
 
3 990 14.2 102 6.54 0.76 (0.60 to 0.98) 
 
4 1198 17.2 126 6.71 0.78 (0.62 to 0.99) 
 
5 983 14.1 103 6.70 0.78 (0.61 to 1.00) 
 
6 - Low 1079 15.5 122 7.34 0.86 (0.68 to 1.08) 
 
Missing 6 0.1 
          
Smoking Non-
smoker 
3489 50.0 376 6.84 1 (ref) 
 
Ex-smoker 2455 35.2 268 7.01 1.03 (0.88 to 1.20) 
 
1-10/day 293 4.2 38 8.37 1.22 (0.88 to 1.71) 
 
11-20/day 336 4.8 38 7.32 1.07 (0.77 to 1.49) 
 
>21/day 178 2.6 25 9.28 1.36 (0.91 to 2.04) 
 
Missing 232 3.3 
          
Longstanding  No 4603 65.9 484 6.68 1.0 
illness Yes 2380 34.1 292 7.95 1.19 (1.03, 1.38)  
Abbreviation: pyrs, person years. 
aDepression Incidence: Number of depressive symptom episodes across phases 1 to 3. 
b  Depression History: Never = no depressive symptom episodes phase 1, 2 or 3; New = 
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episode phase 3 only; Non-chronic = episode once/twice from phase 1 or 2; Chronic = 
episode phase 1, 2, and  
 
Descriptive characteristics  
Table 1 presents the characteristics of the study sample and crude cancer incidence rates 
for selected covariates (see Appendix A for full table). The majority (69.5%) of the sample 
are male. The sample is relatively evenly distributed across each of the age groups, with a 
mean age of 44.4 years (SD=6.04) at phase 1. 74% of the sample had never experienced an 
episode of depressive symptoms. 
 
Log-rank tests showed an association between cancer incidence and age, sex, BMI, 
longstanding illness, physical activity, alcohol consumption (all p<0.05, not shown). The rate-
ratios (table 1; see Appendix A for full table) indicate that the risk of cancer incidence 
increases with age, if participants are female, report longstanding illness, and have a BMI 
greater than 22.4. Those doing 2-5 hours of physical activity appear to have a lower risk of 
cancer incidence than those doing higher or lower levels, whilst those who drink lightly to 
moderately (1-16 units/week) have an increased risk of cancer incidence compared to those 
who never drink and heavier drinkers (17+ units/week).  
 
Log-rank tests for all other covariates were not statistically significant (all p>0.05, not 
shown); although the rate-ratios suggest that those in the highest employment grade (grade 
1) appear to have an increased risk of cancer incidence compared to those in lower grades.  
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Figure 1. Kaplan-Meier survival curves by Depression Incidence (1985-1994), 17.4 year 
follow-up. 
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Figure 2.  Kaplan-Meier survival curves by Depression History (1985-1994), 17.4 year 
follow-up. 
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Figure 1 and 2 show unadjusted cumulative cancer free survival curves with respect 
to Depression Incidence and Depression History. There was no overall difference in survival 
curves with respect to Depression Incidence, Log Rank χ2(3)=3.0, P=0.38, and Depression 
History, LRχ2(3)=4.5, P=0.21. 
The proportional hazard assumption was borderline violated with regard to ‘new’ 
depressive symptoms (LRχ2(3), P=0.05) therefore analysis of Depression History was 
conducted on the first and second half of follow-up: less than 9 years and greater than 9 
years. Figure 2 indicates that participants with ‘new’ depressive symptoms had the lowest 
survival probability until approximately 9 to 10 years of follow-up when survival probability 
appears to increase relative to the other groups.  
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Table 2. Hazard Ratios (HR) for the association between Depression Incidence/Depression History and cancer incidence over a 17.4 year 
follow-up; 776 incident cancer, n=6983. 
    Hazard ratio (95% CI)   
  
Model A:  
Adjusted for age 
and sex 
Model A +  
employment grade 
Fully Adjusteda 
Fully adjusted + 3 
year wash-outb 
Depression Incidencec 
    
 
0 (Never) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 
1 0.95 (0.78, 1.16) 0.95 (0.78, 1.16) 0.94 (0.77, 1.15) 0.95 (0.77, 1.18) 
 
2 0.81 (0.59, 1.11) 0.82 (0.60, 1.12) 0.79 (0.58, 1.09) 0.78 (0.57, 1.08) 
 
3 (Chronic) 1.02 (0.71, 1.47) 1.07 (0.75, 1.54) 1.05 (0.73, 1.52) 1.09 (0.75, 1.57) 
Depression Historyd 
    
 
Never 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
 
New 1.21 (0.89, 1.66) 1.23 (0.90, 1.68) 1.23 (0.89, 1.68) 1.18 (0.85, 1.66) 
 
Non-chronic 0.83 (0.68, 1.02) 0.83 (0.68, 1.02) 0.82 (0.67, 0.99) 0.83 (0.67, 1.02) 
 
Chronic 1.02 (0.71, 1.47) 1.07 (0.75, 1.54) 1.05 (0.73, 1.51) 1.01 (0.68, 1.49) 
a Adjusted  for age sex, employment grade smoking, alcohol consumption, meat consumption, mild physical activity, body-mass-index, systolic 
blood pressure, respiratory illness, and  longstanding illness.  
b 713 incident cancer, n=6887 
c Depression Incidence: Number of depressive symptom episodes across phases 1 to 3. 
d Depression History: Never = no depressive symptom episodes phase 1, 2 or 3; New = episode phase 3 only; Non-chronic = episode 
once/twice from phase 1or 2; Chronic = episode phase 1, 2, and 3. 
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Table 3. Hazard ratios (HR) for the association between Depression History and cancer incidence by follow-up time. 
        < 9 years  > 9 years 
              Hazard Ratio (95% CI)              Hazard Ratio (95% CI) 
  Age and sex 
adjusted 
Fully adjusteda Fully adjusted + 3 
year wash outb 
 Age and sex 
adjusted 
Fully adjusteda 
  (285 incident cancer, n= 6983)  (491 incident cancer, n= 6582) 
Depression historyc      
 
Never 1 (ref) 1 (ref) 1 (ref)  1 (ref) 1 (ref) 
 
New 1.88 (1.23, 2.88) 1.89 (1.23, 2.90) 1.95 (1.21, 3.17)  0.82 (0.51, 1.31) 0.84 (0.52, 1.35) 
 
Non-chronic 0.76 (0.54, 1.08) 0.73 (0.52, 1.04) 0.75 (0.50, 1.10)  0.87 (0.68, 1.12) 0.86 (0.67, 1.11) 
 
Chronic 1.00 (0.55, 1.83) 0.98 (0.53, 1.82) 0.83 (0.38, 1.77)  1.03 (0.66, 1.62) 1.09 (0.69, 1.73) 
a Adjusted for age, sex, employment grade, smoking, alcohol consumption, meat consumption, mild physical activity, body-mass-index, systolic 
blood pressure, respiratory illness, and longstanding illness. 
b 222 incident cancer, n=6887  
c Depression History: Never = no depressive symptom episodes phase 1, 2 or 3; New = episode phase 3 only; Non-chronic = episode 
once/twice from phase 1 or 2; Chronic = episode phase 1, 2, and 3.
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Multivariable Associations 
Table 2 presents associations between Depression Incidence/Depression History and 
cancer incidence over the full 17.4 year follow-up. Neither Depression Incidence nor 
Depression History were significantly associated with cancer incidence in age and sex 
adjusted models. Fully adjusted associations between Depression Incidence/Depression 
History and cancer incidence were almost identical to those adjusted for age and sex only. 
There was little impact on the hazard-ratios after adjusting for each group of potential 
mediators and confounders.  
 
With regard to Depression Incidence, the fully adjusted model shows those who experienced 
one episode of depressive symptoms and those who had ‘chronic’ depressive symptoms 
were no more likely to develop cancer than those who ‘never’ experienced depressive 
symptoms. Participants who experienced two episodes of depressive symptoms appeared to 
have a decreased risk of cancer incidence, although this association did not reach statistical 
significance (HR=0.79, 95% CI: 0.58, 1.09). 
 
With regard to Depression History, there was a borderline association between those who 
had a history of ‘non-chronic’ depressive symptoms and a decreased risk of cancer 
incidence (HR=0.82, 95% CI: 0.67, 0.99). 
 
Table 3 shows that during the first 9 years of follow-up, those with ‘new’ depressive 
symptoms appeared to have an increased risk of developing cancer compared to those who 
‘never’ experienced symptoms (HR=1.89, 95% CI: 1.23, 2.90); this association persisted 
after the inclusion of a 3-year wash-out period. In contrast, over >9 years of follow-up, those 
with ‘new’ depressive symptoms appeared to have a tendency for a reduced risk of 
developing cancer, although this was not statistically significant (HR=0.84 95% CI: 0.52, 
1.35). The hazard ratios for chronic and non-chronic symptoms appear relatively consistent 
over time. Over both periods of follow-up, fully adjusted associations between Depression 
History and cancer incidence were very similar to those adjusted for age and sex only (see 
Appendix 2 for full multivariable models). 
 
Across all crude and multivariable analyses, there was no evidence of an interaction 
between Depression Incidence/Depression History and sex (p=0.12/0.90), or other 
covariates (all interaction coefficients p > 0.05). 
 
Sensitivity Analysis 
The Depression Incidence and Depression History hazard ratios were largely unaffected 
after inclusion of a three-year wash out period (Tables 2 and 3). 
 
Power was too low to present the results by cancer type, although the hazard ratios were 
examined to identify possible trends. Over a 17.4 year follow-up, the age and sex adjusted 
association between Depression Incidence/History and hormone-related cancers (n=311) 
was largely identical compared to all-cancers combined (n=776). However, those with 
chronic symptoms appeared to have an increased risk of smoking-related cancer (n=109; 
HR=1.74, 95% CI: 0.80, 3.76) and a lower risk of other cancers (n=356; HR=0.80, 95% CI: 
0.44, 1.45), compared to hormone-related cancers (HR=1.04, 95% CI: 0.60, 1.82) and all-
cancers combined.  
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Discussion 
This study shows that over a 17.4 year follow-up, ‘chronic’ depressive symptoms 
were not associated with an increased risk of cancer incidence compared to those who 
‘never’ experienced symptoms; there was no evidence of a dose-response relationship. The 
hazard ratio for ‘new’ depressive symptoms was different depending on follow-up time. In the 
first nine years of follow-up, new-onset depressive symptoms were associated with an 
increased risk of cancer incidence; however in later years (> 9 year follow-up), the 
association was attenuated and no longer statistically significant. Unexpectedly, intermittent, 
or ‘non-chronic’ symptoms were associated with a borderline reduced risk.  There was no 
evidence of an interaction between Depression Incidence/History and sex, which is 
consistent with other studies of cancer incidence and mortality [1–3,44,45]. 
 
A comparison of the Depression History and Depression Incidence variables indicates an 
important difference in the role a single episode of depressive symptoms depending on 
when it occurred.  A single episode experienced at either phase 1, 2, or 3 demonstrated no 
apparent association with cancer incidence, whereas a ‘new’ episode experienced at phase 
3 appeared to increase the risk of cancer incidence by 89% in the first 9 years of follow-up. 
This finding is consistent with reverse causality, whereby sub-clinical cancer may lead to 
depressive symptoms; Dantzer et al., [23] suggest that long-term exposure to 
proinflammatory cytokines, such as in sub-clinical cancer, may act directly on the brain to 
elicit sickness behaviour, and the additional development of depressive symptoms in 
vulnerable individuals [22,23]. Animal studies have also shown that tumours may elicit 
depressive and anxiety symptoms in rats, even in the absence of overt sickness behaviours 
[46]. Equally, those with ‘new’ symptoms may be less adapted to cope with emotional stress 
compared to those who have been previously depressed, due to differences in experience, 
expectations and stoicism [47]. The persistence of the association between new depressive 
symptoms and cancer incidence after the inclusion of a 3 year wash-out period suggests that 
the association is not simply due to psychological stress as a result of suspected cancer. 
Previous research has also shown that new depressive symptoms were a better predictor of 
cardiovascular events than those with a history of depressive symptoms [10] and that 
‘recent’ affective disorder was more strongly associated with mortality than ‘lifetime’ affective 
disorder [12].  
 
Those experiencing ‘chronic’ depressive symptoms did not have an increased risk of cancer 
incidence compared to those who ‘never’ experienced symptoms. This is inconsistent with 
previous findings which have reported risk ratios around 2.0 with respect to studies that have 
used measures of chronic depression [4,12,44].  
 
It is plausible that these differential associations could be attributed to methodological 
factors. For example, the study reports all-site cancer incidence only. Cancers are not 
biologically homogenous and as such depression may influence different types of cancer in 
different ways [4]. Sensitivity analysis suggested that the role of chronic depressive 
symptoms could be more important with respect to smoking-related cancers, which made up 
just 14% of the sample. If the effect of chronic symptoms is mediated through behavioural 
pathways, then this could potentially explain the null finding.   
 
Equally, a meta-analysis by Pinquart and Duberstein demonstrated a tendency for stronger 
associations between depression and cancer mortality in those aged over 70 [3]. The current 
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study has a mean participant age of only 44.4 years at baseline, which could help to explain 
the differential associations. Stronger associations observed in older cohorts could suggest 
that depressive scales are simply tapping somatic symptoms of co-morbid disease [3], 
including sub-clinical cancer. All previous studies known to the authors have used 
depressive scales inclusive of somatic symptoms.  
 
It is also possible that the GHQ-subscale cut-off captured moderate, rather than severe 
depressive symptoms, which could have additionally contributed to the null association. 
Stronger associations between depression and cancer incidence and mortality have been 
shown with regard to more severe depressive symptoms, and depression diagnosis 
[2,4,44,48].  
 
Strengths and Limitations 
The strengths of the study include a large sample, high quality prospective data on a wide 
range of confounders and mediators, and a long mean follow-up (15.6 years). Cancer 
incidence data was ascertained for nearly all participants from national cancer register 
linkage, available from 1971. Repeated measures of affective/emotional depressive 
symptoms helped to distinguish between transient and chronic episodes, and were arguably 
less likely to be confounded by symptoms of physical ill health compared to depressive 
scales incorporating somatic items.  
 
The study has several limitations. The  study had low power to explore associations with 
respect to different types of cancer, and also to examine potential interactions, such as 
increased cancer risk in sub-groups such as smokers [5,49,50]. It is also possible that UK 
cancer registry data was underreported during the early years of follow-up [51]; however 
underreporting is unlikely to be related to depressive symptoms and so should not bias 
results – towards the end of follow-up, coverage was estimated to be around 97% [52].  
 
Measures of depressive symptoms in early adulthood were not available so there may be 
some people in the new onset group who experienced symptoms of depression prior to 
inclusion in the study. By restricting our definition of new onset to phase 3 only, we 
attempted to limit this possibility. Using the alternative definition of new onset at both phases 
2 and 3 resulted in weaker associations with cancer incidence over a 9-year follow-up (fully 
adjusted HR=1.54, 95% CI: 1.05-2.24) so our results for new depression may be an 
overestimate. The GHQ depression sub-scale was also shown to have low sensitivity when 
compared with a measure of depression based on a structured psychiatric interview [53].  
 
Most covariates were obtained from phase 3 only; it is possible that measures from earlier 
time-points could play an important role in cancer development, particularly for factors such 
as smoking and alcohol consumption. However, other covariates were known to follow 
strong trajectories, such as systolic blood pressure and BMI [54–56], or were retrospective in 
nature, such as ‘longstanding illness’, which suggests that accounting for earlier measures 
would have been of limited benefit. 
 
There is some evidence of selection bias whereby participants with missing depressive 
symptom data were more likely to smoke, be in a low employment grade, eat fewer fruit and 
vegetables, do fewer hours of physical activity, and report poorer physical health; which 
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could affect external validity. A final consideration is that multiple comparisons were 
conducted which increases the likelihood that the results could be due to chance. 
 
Conclusion 
Previous research has demonstrated that chronic depressive symptoms increase the risk of 
cancer incidence when using measures of depression inclusive of somatic symptoms; yet 
this study found no association with regard to chronic affective/emotional depressive 
symptoms. These differential findings could be due to low numbers of smoking-related 
cancers in our study sample, but may equally emphasise the need to distinguish between 
affective/emotional and somatic symptoms of depression. 
 
New-onset depressive symptoms were associated with an increased-risk of cancer 
incidence, which is consistent with reverse causality as a result of inflammatory processes. 
It is possible that the aetiology of adult ‘new-onset’ depression is distinct to that of chronic 
depression. 
 
Overall, this study highlights the importance of further research with regard to the 
relationship between life course profiles of depression and cancer incidence. If new-onset 
depression is found to predict cancer incidence, then this could serve as an important 
marker for the development of the disease. 
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Caption titles: 
 
Figure 1. Kaplan-Meier survival curves by Depression Incidence (1985-1994), 17.4 year 
follow-up. 
 
Figure 2.  Kaplan-Meier survival curves by Depression History (1985-1994), 17.4 year 
follow-up. 
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Appendix A:   
Table A.1. Descriptive characteristics of the study sample and crude cancer incidence rates; 
n=6983, 776 incident cancer (full table). 
Characteristic N % 
Incident 
cancer 
Rate 
(per 
1000 
pyrs) 
Rate ratio  
(95% CI) 
Depression 0 - Never 5167 74.0 589 7.29 1 (ref) 
Incidencea 1 occasion 1084 15.5 114 6.75 
0.93 (0.76 to 
1.13) 
 
2 
occasions 470 6.7 42 5.68 
0.78 (0.57 to 
1.07) 
 
3 - 
Chronic 262 3.8 31 7.61 
1.04 (0.73 to 
1.50) 
       
Depression  Never 5,167 74.0 589 7.29 1 (ref) 
Historyb New  346 5.0 42 7.94 
1.09 (0.80 to 
1.49) 
 
Non-
chronic 1,208 17.3 114 6.00 
0.82 (0.67 to 
1.00) 
 
Chronic 262 3.8 31 7.61 
1.04 (0.73 to 
1.50) 
       
Age group 35-39 1932 27.7 106 3.40 1.0 
 
40-44 1794 25.7 166 5.79 
1.70 (1.33 to 
2.17) 
 
45-49 1419 20.3 160 7.25 
2.13 (1.67 to 
2.73) 
 
50-56 1838 26.3 344 12.62 
3.71 (2.99 to 
4.62) 
       
Sex Male 4856 69.5 507 6.66 1.0 
 
Female 2127 30.5 269 8.14 
1.22 (1.06 to 
1.42) 
       
Employment  1 - High 1217 17.4 163 8.57 1 (ref) 
grade 2 1510 21.6 158 6.66 
0.78 (0.63 to 
0.97) 
 
3 990 14.2 102 6.54 
0.76 (0.60 to 
0.98) 
 
4 1198 17.2 126 6.71 
0.78 (0.62 to 
0.99) 
 
5 983 14.1 103 6.70 
0.78 (0.61 to 
1.00) 
 
6 - Low 1079 15.5 122 7.34 
0.86 (0.68 to 
1.08) 
 
Missing 6 0.1 
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Smoking 
Non-
smoker 3489 50.0 376 6.84 1 (ref) 
 
Ex-smoker 2455 35.2 268 7.01 
1.03 (0.88 to 
1.20) 
 
1-10/day 293 4.2 38 8.37 
1.22 (0.88 to 
1.71) 
 
11-20/day 336 4.8 38 7.32 
1.07 (0.77 to 
1.49) 
 
>21/day 178 2.6 25 9.28 
1.36 (0.91 to 
2.04) 
 
Missing 232 3.3 
   Alcohol units None 1336 19.1 127 6.09 1 (ref) 
grams p/wk 1 – 3 1254 18.0 149 7.60 
1.25 (0.99 to 
1.58) 
 
4 – 7 1350 19.3 170 8.05 
1.32 (1.05 to 
1.66) 
 
8 – 16 1620 23.2 189 7.48 
1.23 (0.98 to 
1.54) 
 
17+ 1417 20.3 140 6.29 
1.03 (0.81 to 
1.31) 
 
Missing 6 0.1 
          
Physical 
activity 0 – 1 811 11.6 91 7.23 1 (ref) 
hrs p/wk 2 – 3 1426 20.4 136 6.02 
0.83 (0.64 to 
1.09) 
 
4 – 5 1512 21.7 149 6.24 
0.86 (0.67 to 
1.12) 
 
6 – 9 1452 20.8 178 7.91 
1.09 (0.85 to 
1.41) 
 
10+ 1782 25.5 222 8.04 
1.11 (0.87 to 
1.42) 
       
Meat  0-3/month 707 10.1 81 7.35 1 (ref) 
consumption 1-2/week 1335 19.1 146 7.03 
0.96 (0.73 to 
1.25) 
 
3-4/week 2565 36.7 289 7.19 
0.98 (0.76 to 
1.25) 
 
5-6/week 1751 25.1 185 6.72 
0.91 (0.70 to 
1.19) 
 
>7/week 615 8.8 74 7.76 
1.05 (0.77 to 
1.45) 
 
Missing 10 0.1 
          
Longstanding  No 4603 65.9 484 6.68 1 (ref) 
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Illness Yes 2380 34.1 292 7.95 
1.19 (1.03 to 
1.38) 
       
Respiratory 
illness No 6508 93.2 722 7.09 1 (ref) 
 Yes 470 6.7 52 7.15 
1.01 (0.76 to 
1.34) 
 Missing 5     
       
Body mass 
index 15.0-22.39 1344 19.3 106 4.96 1 (ref) 
 
22.4-24.09 1344 19.3 140 6.62 
1.33 (1.04  to  
1.72) 
 
24.1-25.59 1367 19.6 170 7.95 
1.60 (1.26  to  
2.04) 
 
25.6-27.79 1331 19.1 162 7.76 
1.56 (1.22  to  
2.00) 
 
27.8+ 1287 18.4 150 7.48 
1.50 (1.18  to  
1.93) 
 
Missing 310 4.4 
          
Systolic blood 52-108 1247 17.9 140 7.09 1 (ref) 
pressure, 
mmHg 109-115 1240 17.8 123 6.26 
0.88 (0.69 to 
1.13) 
 
116-122 1410 20.2 149 6.72 
0.95 (0.75 to 
1.19) 
 
123-131 1393 20.0 147 6.73 
0.95 (0.75 to 
1.19) 
  132+ 1387 19.9 169 7.88 
1.11 (0.88 to 
1.39) 
 
Missing 306 4.4 
   
Abbreviation: pyrs, person years.  
aDepression Incidence: Number of depressive symptom episodes across phases 1 to 3. 
b  Depression History: Never = no depressive symptom episodes phase 1, 2 or 3; New = 
episode phase 3 only; Non-chronic = episode once/twice from phase 1 or 2; Chronic = 
episode phase 1, 2, and 3. 
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Appendix B:  Fully adjusted models for the association between Depression Incidence / 
Depression History and cancer incidence (full results). 
Table B.1. Fully adjusted hazard Ratios for the association between Depression 
Incidence/covariates and cancer incidence over a 17.4 year follow-up; 776 incident cancer, 
n=6983. 
  
Hazard ratiob  
(95% CI) 
Depression 0 - Never 1 (ref)  
Incidencea 1 occasion 0.94 (0.77, 1.15) 
 
2 occasions 0.79 (0.58, 1.08) 
 
3 - Chronic 1.05 (0.73, 1.52) 
  
 
Age (continuous) 1.09 (1.08, 1.10) 
  
 
Sex Male 1 (ref)  
 
Female 1.32 (1.10, 1.59) 
  
 
Employment  1 - High 1 (ref)  
Grade 2 0.90 (0.72, 1.12) 
 
3 0.89 (0.69, 1.14) 
 
4 0.87 (0.68, 1.10) 
 
5 0.72 (0.55, 0.94) 
 
6 - Low 0.66 (0.50, 0.88) 
  
 
Smoking Non-smoker 1 (ref)  
 
Ex-smoker 0.95 (0.81, 1.12) 
 
1-10/day 1.28 (0.91, 1.79) 
 
11-20/day 1.16 (0.82, 1.63) 
 
>21/day 1.57 (1.05, 2.37) 
  
 
Alcohol units None 1 (ref)  
grams p/wk 1 – 3 1.27 (1.00, 1.62) 
 
4 – 7 1.40 (1.10, 1.77) 
 
8 – 16 1.35 (1.06, 1.71) 
 
17+ 1.20 (0.93, 1.56) 
  
 
Physical activity (hours p/wk) 1.01 (1.00, 1.02) 
  
 
Body mass 15.0-22.39 1 (ref)  
Index 22.4-24.09 1.25 (0.97, 1.63) 
 
24.1-25.59 1.51 (1.18, 1.93) 
 
25.6-27.79 1.41 (1.10, 1.82) 
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27.8+ 1.39 (1.08, 1.79) 
  
 
Longstanding  No 1 (ref)  
Illness Yes 1.11 (0.95, 1.28) 
  
 
Systolic blood 52-108 1 (ref)  
pressure, 
mmHg 109-115 
0.84 (0.66, 1.07) 
 
116-122 0.88 (0.69, 1.11) 
 
123-131 0.83 (0.65, 1.06) 
  132+ 0.85 (0.67, 1.07) 
  
 
Respiratory No 1 (ref)  
illness Yes 0.94 (0.7, 1.25) 
  
 
Meat  0-3/month 1 (ref)  
consumption 1-2/week 0.86 (0.65, 1.13) 
 
3-4/week 0.85 (0.66, 1.09) 
 
5-6/week 0.82 (0.63, 1.07) 
 
>7/week 0.98 (0.71, 1.36) 
aDepression Incidence: Number of depressive symptom episodes across phases 1 to 3. 
b Adjusted for age, sex, employment grade, smoking, alcohol consumption, meat 
consumption, mild physical activity, body-mass-index, systolic blood pressure, respiratory 
illness, and longstanding illness. 
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Table B.2. Fully adjusted hazard ratios for the association between Depression 
History/covariates and cancer incidence over a 17.4 year follow-up; 776 incident cancer, 
n=6983. 
 
  
Hazard ratiob  
(95% CI) 
Depression  Never 1 (ref)  
Historya New  1.23 (0.89, 1.68) 
 
Non-chronic 0.82 (0.67, 1.00) 
 
Chronic 1.05 (0.73, 1.52) 
  
 
Age (continuous) 1.09 (1.08, 1.11) 
  
 
Sex Male 1 (ref)  
 
Female 1.33 (1.11, 1.59) 
  
 
Employment  1 - High 1 (ref)  
Grade 2 0.90 (0.72, 1.13) 
 
3 0.89 (0.69, 1.14) 
 
4 0.87 (0.68, 1.10) 
 
5 0.72 (0.55, 0.94) 
 
6 - Low 0.66 (0.50, 0.87) 
  
 
Smoking Non-smoker 1 (ref)  
 
Ex-smoker 0.95 (0.81, 1.12) 
 
1-10/day 1.27 (0.91, 1.78) 
 
11-20/day 1.15 (0.82, 1.62) 
 
>21/day 1.56 (1.04, 2.35) 
  
 
Alcohol units None 1 (ref)  
grams p/wk 1 – 3 1.27 (1.00, 1.62) 
 
4 – 7 1.40 (1.11, 1.78) 
 
8 – 16 1.36 (1.07, 1.72) 
 
17+ 1.21 (0.93, 1.58) 
  
 
Physical activity (hours p/wk) 1.01 (1.00, 1.02) 
  
 
Body mass 15.0-22.39 1 (ref)  
Index 22.4-24.09 1.26 (0.97, 1.63) 
 
24.1-25.59 1.52 (1.19, 1.94) 
 
25.6-27.79 1.41 (1.10, 1.81) 
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27.8+ 1.39 (1.08, 1.80) 
  
 
Longstanding  No 1 (ref)  
Illness Yes 1.11 (0.95, 1.28) 
  
 
Systolic blood 52-108 1 (ref)  
pressure, 
mmHg 109-115 
0.84 (0.66, 1.07) 
 
116-122 0.88 (0.70, 1.11) 
 
123-131 0.83 (0.65, 1.06) 
  132+ 0.85 (0.67, 1.07) 
  
 
Respiratory No 1 (ref)  
illness Yes 0.94 (0.70, 1.25) 
  
 
Meat  0-3/month 1 (ref)  
consumption 1-2/week 0.86 (0.65, 1.13) 
 
3-4/week 0.85 (0.66, 1.10) 
 
5-6/week 0.82 (0.62, 1.07) 
 
>7/week 0.98 (0.71, 1.36) 
a  Depression History: Never = no depressive symptom episodes phase 1, 2 or 3; New = 
episode phase 3 only; Non-chronic = episode once/twice from phase 1 or 2; Chronic = 
episode phase 1, 2, and 3 
b Adjusted for age, sex, employment grade, smoking, alcohol consumption, meat 
consumption, mild physical activity, body-mass-index, systolic blood pressure, respiratory 
illness, and longstanding illness. 
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Table B.3. Fully adjusted hazard ratios for the association between Depression 
History/covariates and cancer incidence by follow-up time. 
  
Hazard ratiob  
(95% CI) 
  < 9 year > 9 year 
  
(285 incident cancer,  
n= 6983) 
(491 incident cancer, 
n= 6582) 
Depression  Never 1 (ref)  1 (ref)  
Historya New  1.89 (1.23, 2.90) 0.84 (0.52, 1.35) 
 
Non-chronic 0.73 (0.52, 1.04) 0.86 (0.67, 1.11) 
 
Chronic 0.98 (0.53, 1.82) 1.09 (0.69, 1.73) 
  
 
 
Age (continuous) 1.10 (1.07, 1.12) 1.09 (1.07, 1.11) 
  
 
 
Sex Male 1 (ref)  1 (ref)  
 
Female 1.75 (1.31, 2.34) 1.11 (0.88, 1.41) 
  
 
 
Employment  1 - High 1 (ref)  1 (ref)  
Grade 2 0.99 (0.66, 1.47) 0.87 (0.67, 1.13) 
 
3 1.10 (0.71, 1.69) 0.80 (0.59, 1.09) 
 
4 1.06 (0.70, 1.60) 0.79 (0.58, 1.06) 
 
5 1.00 (0.64, 1.55) 0.59 (0.41, 0.83) 
 
6 - Low 0.77 (0.48, 1.21) 0.62 (0.44, 0.88) 
  
 
 
Smoking Non-smoker 1 (ref)  1 (ref)  
 
Ex-smoker 1.13 (0.87, 1.47) 0.86 (0.70, 1.05) 
 
1-10/day 1.04 (0.57, 1.89) 1.41 (0.94, 2.12) 
 
11-20/day 1.12 (0.64, 1.97) 1.17 (0.77, 1.79) 
 
>21/day 1.48 (0.71, 3.08) 1.61 (0.97, 2.65) 
  
 
 
Alcohol units None 1 (ref)  1 (ref)  
grams p/wk 1 – 3 1.35 (0.93, 1.97) 1.23 (0.90, 1.67) 
 
4 – 7 1.36 (0.92, 2.00) 1.43 (1.05, 1.93) 
 
8 – 16 1.45 (0.99, 2.14) 1.30 (0.95, 1.76) 
 
17+ 1.13 (0.72, 1.76) 1.25 (0.90, 1.73) 
  
 
 
Physical activity (hours p/wk) 1.01 (1.00, 1.03) 1.01 (1.00, 1.02) 
  
 
 
Body mass 15.0-22.39 1 (ref)  1 (ref)  
Index 22.4-24.09 1.24 (0.82, 1.88) 1.27 (0.89, 1.80) 
 
24.1-25.59 1.17 (0.78, 1.74) 1.78 (1.29, 2.46) 
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25.6-27.79 1.06 (0.71, 1.58) 1.67 (1.20, 2.33) 
 
27.8+ 1.10 (0.73, 1.65) 1.61 (1.15, 2.27) 
  
 
 
Longstanding  No 1 (ref)  1 (ref)  
Illness Yes 1.14 (0.89, 1.45) 1.09 (0.9, 1.31) 
  
 
 
Systolic blood 52-108 1 (ref)  1 (ref)  
pressure, 
mmHg 109-115 
0.90 (0.59, 1.37) 0.80 (0.59, 1.09) 
 
116-122 1.13 (0.76, 1.68) 0.76 (0.57, 1.02) 
 
123-131 1.02 (0.68, 1.52) 0.74 (0.55, 1.00) 
  132+ 1.06 (0.71, 1.57) 0.75 (0.56, 1.00) 
  
 
 
Respiratory No 1 (ref)  1 (ref)  
illness Yes 0.85 (0.52, 1.41) 0.99 (0.69, 1.41) 
  
 
 
Meat  0-3/month 1 (ref)  1 (ref)  
consumption 1-2/week 0.76 (0.50, 1.14) 0.95 (0.65, 1.38) 
 
3-4/week 0.68 (0.47, 1.00) 1.00 (0.71, 1.41) 
 
5-6/week 0.61 (0.40, 0.93) 0.99 (0.69, 1.42) 
 
>7/week 0.77 (0.46, 1.30) 1.15 (0.76, 1.76) 
a  Depression History: Never = no depressive symptom episodes phase 1, 2 or 3; New = 
episode phase 3 only; Non-chronic = episode once/twice from phase 1 or 2; Chronic = 
episode phase 1, 2, and 3 
b Adjusted for age, sex, employment grade, smoking, alcohol consumption, meat 
consumption, mild physical activity, body-mass-index, systolic blood pressure, respiratory 
illness, and longstanding illness. 
 
